Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

Using liver AST levels to predict outcomes for patients with diffuse large B-cell lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the impact of aspartic transaminase (AST) levels in the blood on survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that high levels of AST in the blood were associated with poorer treatment outcomes for these patients. Some background DLBCL is one of the most common types...

Read More

Evaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...

Read More

Evaluating polatuzumab vedotin with chemoimmunotherapy for diffuse large B-cell lymphoma

Posted by on Jun 5, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (Pola) combined with chemoimmunotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that combining Pola with these regimens was promising, with manageable side effects. Some background DLBCL is one of the most common types...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...

Read More

Evaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL

Posted by on May 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...

Read More

Evaluating ibrutinib plus nivolumab for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Feb 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...

Read More

Evaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More

Comparing outcomes after adding two doses of rituximab to R-CHOP chemotherapy for aggressive B-cell lymphoma

Posted by on Jan 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of six versus eight doses of rituximab (Rituxan) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with aggressive B-cell lymphoma. This study concluded that adding two extra doses of rituximab to R-CHOP had similar outcomes in these...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More